<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02943460</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-428-4025</org_study_id>
    <secondary_id>2016-002442-23</secondary_id>
    <nct_id>NCT02943460</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Efficacy of GS-9674 in Adults With Primary Sclerosing Cholangitis Without Cirrhosis</brief_title>
  <acronym>PSC-Phase 2</acronym>
  <official_title>A Phase 2, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects With Primary Sclerosing Cholangitis Without Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the safety and tolerability of GS-9674 in
      adults with primary sclerosing cholangitis (PSC).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 29, 2016</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Actual">February 28, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>Up to 12 weeks plus 30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Serious Adverse Events</measure>
    <time_frame>Up to 12 weeks plus 30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of treatment-emergent laboratory abnormalities</measure>
    <time_frame>Up to 12 weeks plus 30 days</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Primary Sclerosing Cholangitis</condition>
  <arm_group>
    <arm_group_label>GS-9674 30 mg (Blinded Study Phase)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GS-9674 30 mg + placebo to match GS-9674 100 mg for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GS-9674 100 mg (Blinded Study Phase)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GS-9674 100 mg + placebo to match GS-9674 30 mg for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Blinded Study Phase)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to match GS-9674 30 mg + placebo to match GS-9674 100 mg for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GS-9674 (Open Label Extension Phase)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following the Blinded Study Phase, eligible participants may have the option to receive GS-9674 for an additional 96 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-9674</intervention_name>
    <description>Tablet(s) administered orally once daily</description>
    <arm_group_label>GS-9674 30 mg (Blinded Study Phase)</arm_group_label>
    <arm_group_label>GS-9674 100 mg (Blinded Study Phase)</arm_group_label>
    <arm_group_label>GS-9674 (Open Label Extension Phase)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to match GS-9674</intervention_name>
    <description>Tablet(s) administered orally once daily</description>
    <arm_group_label>GS-9674 30 mg (Blinded Study Phase)</arm_group_label>
    <arm_group_label>GS-9674 100 mg (Blinded Study Phase)</arm_group_label>
    <arm_group_label>Placebo (Blinded Study Phase)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Diagnosis of PSC based on cholangiogram (magnetic resonance cholangiopancreatography
             (MRCP), endoscopic retrograde cholangiopancreatography (ERCP), or percutaneous
             transhepatic cholangiogram (PTC)) within the previous 12 months

          -  Serum alkaline phosphatase (ALP) &gt; 1.67 x upper limit of the normal range (ULN)

          -  For individuals on ursodeoxycholic acid (UDCA), the dose of UDCA must have been stable
             for at least 12 months prior to screening through the end of treatment. For
             individuals not on UDCA, no UDCA use for at least 12 months before screening through
             the end of treatment

          -  Screening FibroSURE/FibroTest® &lt;0.75 unless a historical liver biopsy within 12 months
             of screening does not reveal cirrhosis. In adults with Gilbert's syndrome or
             hemolysis, FibroSURE/FibroTest® will be calculated using direct bilirubin instead of
             total bilirubin.

        Key Exclusion Criteria:

          -  Alanine aminotransferase (ALT) &gt; 10 x ULN

          -  Total bilirubin &gt; 2 x ULN

          -  International normalized ratio (INR) &gt; 1.2 unless on anticoagulant therapy

          -  Small-duct PSC (histologic evidence of PSC with normal bile ducts on cholangiography)

          -  Other causes of liver disease including secondary sclerosing cholangitis and viral,
             metabolic, alcoholic, and other autoimmune conditions

          -  Ascending cholangitis within 60 days of screening

          -  Presence of a percutaneous drain or bile duct stent

          -  Use of fibrates or obeticholic acid within 3 months prior to screening through the end
             of treatment

          -  Cirrhosis of the liver as defined by any of the following:

               -  Historical liver biopsy demonstrating cirrhosis (eg, Ludwig stage 4 or Ishak
                  stage ≥ 5)

               -  Prior history of decompensated liver disease, including ascites, hepatic
                  encephalopathy or variceal bleeding

               -  Liver stiffness &gt; 14.4 kPa by FibroScan

          -  Current, active inflammatory bowel disease (IBD) defined as a partial Mayo score of &gt;
             1 and/or a score on the Rectal Bleeding domain &gt; 0.

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lakewood Ranch</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norwich</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Canada</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2016</study_first_submitted>
  <study_first_submitted_qc>October 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2016</study_first_posted>
  <last_update_submitted>March 29, 2018</last_update_submitted>
  <last_update_submitted_qc>March 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Cholangitis, Sclerosing</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

